This is very much not my style! I like to do my research, make sure I’ve evaluated all angles, shore up the details, and THEN dive in with both feet. But today I don’t have time for that!
Last night my husband’s colleague Bonnie pulled me aside at dinner to tell me about an article she’d read in the local law journal. The room was crowded and I knew I wasn’t going to “get it” and so she offered to send me it to me. It just arrived. TWO amazing gifts from ONE amazing company: VIRATECH.
(Now, let’s hope that in my rush to share I don’t get this all wrong…)
First, a NEW social media site (still in beta) designed specifically for cancer patients. Think Facebook for the cancer patient, caregiver, provider…with content, support, and more, all among people who “get it.” You get the picture. Check it out:
(P.S. Let’s not lose sight of the fact that I just managed to get my first video up here! But I digress…)
Pretty exciting stuff, if you ask me! I’m looking forward to getting in on the ground floor of this.
But it’s not the most exciting part…
We talk a lot about changing the face of cancer research.
We need impact.
We need collaboration.
We need to reward taking chances over incremental change.
We need a new model…
The Antidote to Myriad
As many of you know, there is a Supreme Court case pending against Myriad Genetics in their effort to secure a patent on the BRCA 1 and BRCA 2 genes. There are all kinds of things to say about it, but let’s go with AWFUL and move on. (You can learn more here: BC Action on Gene Patenting). Imagine, a company that so badly wants to control progress that they seek to patent the genes we were born with. In fact, they just won a similar case in Australia.
Unfortunately I can’t link to the Daily Journal article because it is a member, fee-based site. But in the article author Kenneth Eade uses Avastin as a model of how progress is made in the world of heathcare. Last year Avastin hit $2.66 billion (yes, with a “B”) in sales in the US, and nearly $6B world-wide. It arrived in the US 16 years ago, and was first approved by the FDA as a metastatic cancer treatment in 2004.
Kade goes on to discuss what’s happened with your cell phone in the last 16 years. I can tell you, because the one I had back then was, I kid you not, sold to me as a phone/weapon. Remember this >
To what can we attribute the rapid explosion of new, creative technology at accessible pricing?
And that is what Viratech is looking to bring us – an open-source, collaborative platform for biotech. It’s modified open-source, as researchers will still be able to protect their intellectual property but connect with others to collaborate and even crowd-fund their projects, but ultimately it’s about working together in news ways, and I LIKE that!
So with guarded optimism, I have contacted the company, and I will share more as learn!